The North American Menopause Society (NAMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NAMS designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Explain how recent findings from the Women’s Health Initiative and other studies fill knowledge gaps about the “critical window” hypothesis, differences among hormone therapy (HT) formulations, and the role of risk stratification in individualizing decisions about HT
- Describe the role of estrogen in menopause-associated mood disturbances and apply evidence-based strategies (hormonal and nonhormonal) to manage these disturbances
- Recognize and explain to patients the impact of route of administration of systemic estrogen (oral vs. nonoral) on the overall risk-to-benefit ratio of HT
- Choose among available forms of progestogen therapy to optimally balance quality-of-life issues, cardiovascular effects, and endometrial protection for individual patients
- Summarize comparative safety and efficacy data for FDA-approved vs. custom-compounded bioidentical HT preparations, and counsel patients on concerns and risks surrounding custom-compounded preparations
- Outline a plan for managing hot flashes and other symptoms of menopause in women who present with complicating factors such as a history of breast cancer or deep venous thrombosis
NAMS designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Learning Objectives
At the conclusion of the NAMS Annual Meeting, participants should be able to:
- Translate the scientific evidence on key menopause-related issues to clinical practice
- Appropriately integrate findings from various imaging modalities in light of dramatically increased imaging sensitivity
- Evaluate midlife women for depressive symptoms, recognizing the patterns of association between depression and menopause-associated symptoms
- Initiate individualized treatment plans for vaginal atrophy and dyspareunia in peri- and postmenopausal women
- Incorporate cardiovascular risk assessment, as established by American Heart Association guidelines on cardiovascular disease prevention in women, into midlife women’s annual visits
- Explain whether, when, and why hormone therapy might ever be an appropriate option for an asymptomatic postmenopausal woman
- Recognize risk factors for arthralgias in patients taking aromatase inhibitors for breast cancer, counsel patients on this risk, and describe the impact of arthralgias on treatment adherence
- Counsel peri- and postmenopausal women on recommended levels of vitamin D and calcium intake for optimal bone and overall health using evidence-based guidelines
- Draw on current understanding of the cardiometabolic effects of endogenous androgens to counsel postmenopausal women on the possible role of these hormones not only in sexual function but also in diabetes, metabolic syndrome, and cardiovascular disease
- Recognize typical presentations of abuse and neglect in older women, and outline appropriate actions when abuse or neglect is suspected
- Engage midlife women in identifying wellness-promoting habits they can initiate in their lives
On Thursday and Friday mornings of the 2011 Annual Meeting, there will also be “Meet the Experts” CME breakfast sessions offered at a small additional fee.
NAMS designates each of these live activities for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |